2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N0830S
    Palmitic acid-1,2,3,4-13C4 287100-89-4 ≥99.0%
    Palmitic acid-1,2,3,4-13C4 is the 13C-labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants. Palmitic acid can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells.
    Palmitic acid-1,2,3,4-13C4
  • HY-Y0669R
    Pipecolic acid (Standard) 535-75-1
    Pipecolic acid (Standard) is the analytical standard of Pipecolic acid. This product is intended for research and analytical applications. Pipecolic acid is a metabolite of lysine and an important precursor for many useful microbial secondary metabolites. Pipecolic acid slows ferroptosis in diabetic retinopathy by inhibiting the YAP-GPX4 signaling pathway. In addition, Pipecolic acid can be used as a diagnostic marker for pyridoxine-dependent epilepsy.
    Pipecolic acid (Standard)
  • HY-Y0892R
    4-Hydroxybenzyl alcohol (Standard) 623-05-2
    4-Hydroxybenzyl alcohol (Standard) is the analytical standard of 4-Hydroxybenzyl alcohol. This product is intended for research and analytical applications. 4-Hydroxybenzyl alcohol is a phenolic compound widely distributed in various kinds of plants. Anti-inflammatory, anti-oxidant, anti-nociceptive activity. Neuroprotective effect. Inhibitor of tumor angiogenesis and growth[4].
    4-Hydroxybenzyl alcohol (Standard)
  • HY-100740C
    (1α,1'S,4β)-Lanabecestat 1384082-96-5
    (1α,1'S,4β)-Lanabecestat ((1α,1'S,4β)-AZD3293) a less active enantiomer of Lanabecestat. Lanabecestat is a potent, orally active and blood-brain barrier penetrating BACE1 inhibitor with a Ki of 0.4 nM.
    (1α,1'S,4β)-Lanabecestat
  • HY-101183A
    THK5351 (R enantiomer) 2101218-44-2
    THK5351 R enantiomer is an R enantiomer of THK5351.
    THK5351 (R enantiomer)
  • HY-101281B
    (R)-VU 6008667 2097818-14-7 99.79%
    (R)-VU 6008667, the less active (R)-enantiomer to VU 6008667, is devoid of M5 NAM activity (IC50>10 μM).
    (R)-VU 6008667
  • HY-107457A
    AZD-8529 mesylate 1314217-69-0 99.63%
    AZD-8529 mesylate is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2, with an EC50 of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes.
    AZD-8529 mesylate
  • HY-17406S1
    Tolcapone-d4 1246816-93-2 99.13%
    Tolcapone-d4 is the deuterium labeled Tolcapone. Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC50 of 773?nM in the liver. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma.
    Tolcapone-d4
  • HY-W015229R
    3-Indolepropionic acid (Standard) 830-96-6
    3-Indolepropionic acid (Standard) is the analytical standard of 3-Indolepropionic acid. This product is intended for research and analytical applications. 3-Indolepropionic acid is shown to be a powerful antioxidant and has potential in the treatment for Alzheimer’s disease. In Vitro: 3-Indolepropionic acid is shown to be a powerful antioxidant and has potential in the treatment for Alzheimer’s disease. 3-Indolepropionic acid is a more potent scavenger of hydroxyl radicals than melatonin. Similar to melatonin but unlike other antioxidants, 3-Indolepropionic acid scavenges radicals without subsequently generating reactive and pro-oxidant intermediate compounds. It is also suggested that indolepropionic acid, a gut microbiota-produced metabolite, is a potential biomarker for the development of type 2 diabetes (T2D) that may mediate its protective effect by preservation of β-cell function.
    3-Indolepropionic acid (Standard)
  • HY-12131
    DMP 696 202578-52-7 99.03%
    DMP 696 is a selective corticotropin-releasing hormone receptor 1 (CRHR1) antagonist, used for the treatment of anxiety and depression.
    DMP 696
  • HY-17615
    Fosnetupitant 1703748-89-3
    Fosnetupitant (Pronetupitant) a methylene phosphate proagent of Netupitant. Fosnetupitant (Pronetupitant) exhibits a pKi of 9.5 for human NK1 receptor.
    Fosnetupitant
  • HY-10019A
    Varenicline dihydrochloride 866823-63-4 99.21%
    Varenicline (CP 526555-18) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation.
    Varenicline dihydrochloride
  • HY-107732
    JNJ-5207787 683746-68-1 ≥98.0%
    JNJ-5207787 is a nonpeptidic, selective and penetrate the blood-brain barrier neuropeptide Y Y2 receptor (Y2) antagonist. JNJ-5207787 inhibits the binding of peptide YY (PYY) with pIC50s of 7.0 and 7.1 for human Y2 receptor and rat Y2 receptor, respectively. JNJ-5207787 is >100-fold selective versus human Y1, Y4, and Y5 receptors.
    JNJ-5207787
  • HY-108321
    Zofenopril 81872-10-8 98.81%
    Zofenopril is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 81 μM.
    Zofenopril
  • HY-108403
    Phenibut 1078-21-3
    Phenibut (β-Phenyl-GABA) is a GABA-B agonist. Phenibut acts as a GABA-mimetic, primarily at GABAB receptors. Phenibut has anxiolytic and nootropic (cognition enhancing) effects.
    Phenibut
  • HY-109150
    Mesdopetam 1403894-72-3 98%
    Mesdopetam (IRL790) is a dopamine D3 receptor antagonist (Ki=90 nM; IC50=9.8 μM for human recombinant D3 receptor) with psychomotor stabilizing properties. Mesdopetam is used for the research of motor and psychiatric complications in Parkinson disease.
    Mesdopetam
  • HY-109167
    Aramisulpride 71675-90-6 99.49%
    Aramisulpride is a dopamine D2 receptor and serotonin receptor antagonist used for the research of metabolic disorders.
    Aramisulpride
  • HY-111500
    (Rac)-NMDAR antagonist 1 2435557-99-4 ≥98.0%
    (Rac)-NMDAR antagonist 1 is the racemate of NMDAR antagonist 1. NMDAR antagonist 1 is a potent and orally bioavailable NR2B-selective NMDAR antagonist.
    (Rac)-NMDAR antagonist 1
  • HY-111751
    JNJ-61432059 2035814-50-5 99.18%
    JNJ-61432059 is an oral active and selective negative modulator of AMPAR associated with trans-membrane AMPAR regulatory protein (TARP) γ-8, with a pIC50 of 9.7 for GluA1/γ-8. Exhibits time- and dose-dependent AMPAR/γ-8 receptor occupancy in mouse hippocampus, resulting in robust seizure protection in corneal kindling and pentylenetetrazole (PTZ) anticonvulsant models.
    JNJ-61432059
  • HY-112913
    SOCE inhibitor 1 2169316-15-6 99.73%
    SOCE inhibitor 1 is a store-operated calcium entry (SOCE) inhibitor with an IC50 of 4.4 μM.
    SOCE inhibitor 1
Cat. No. Product Name / Synonyms Application Reactivity